Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).